RNS Number : 3506B Nuformix PLC 06 June 2019

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ :			Nuformix PLC			
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)						
Non-UK issuer						
2. Reason for the	notification (please	mark the app	ropriate	e box or boxes with a	an "X")	
An acquisition or dis	posal of voting rights					Х
An acquisition or dis	posal of financial instr	uments				
An event changing the breakdown of voting rights						
Other (please specify) ⁱⁱⁱ :						
3. Details of person subject to the notification obligation ^{iv}						
Name			SPREADEX LTD			
City and country of registered office (if applicable)			St Albans, UK			
4. Full name of shareholder(s) (if different from 3.) ^v						
Name						
City and country of registered office (if applicable)						
5. Date on which the threshold was crossed or reached ^{vi} :						
6. Date on which issuer notified (DD/MM/YYYY):			03/06/2019			
7. Total positions of person(s) subject to the notification obligation						
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.E 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer ^{vii}	
Resulting situation on the date on which threshold was crossed or reached	4.95%	-1		4.95%	460,750,000	
Position of previous notification (if applicable)	5.66%	0.01%		5.67%		

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^{viii}				
A: Voting rights atta	ached to shares			
Class/type of shares	Number of voting rig	hts ^{ix}	% of voting rights	
ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BYW79Y38	22,818,894		4.95%	
SUBTOTAL 8. A	22,818,894		4.95%	

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ^x	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
	1	SUBTOTAL 8. B 1		

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date ^X	Exercise/ Conversion Period ^{xi}	Physical or cash settlement ^{Xii}	Number of voting rights	% of voting rights
	1		SUBTOTAL 8.B.2		

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{Xiii} Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{XiV} (please add additional rows as necessary)	Х
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{XiV} (please add additional rows as necessary)	
(please add additional rows as necessary)	
Name ^{XV} Name ^X	he

		•
10. In case of proxy votin	g, please identify:	
Name of the proxy holde	r	
The number and % of vo	ting rights held	
The date until which the	voting rights will be held	
11. Additional informat	ion ^{xvi}	
David Carbon		

11. Additional information ^{xvi}	
David Corben	
01727895193	

Place of completion	UK
Date of completion	03/06/2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END